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Bordetella pertussis and Bordetella bronchiseptica rely on the global two-component regulatory system BvgAS to control expres-
sion of distinct phenotypic phases. In the Bvg phase, expression of vrg genes, including those required for motility in B. bron-
chiseptica, is activated and genes encoding virulence factors are not expressed. Conversely, in the Bvg phase, genes encoding
virulence factors are highly expressed while genes necessary for motility are repressed. Although several genetic analyses have
demonstrated the importance of the Bvg phase during respiratory infection, Bvg-regulated gene activation in B. bronchiseptica
has not been investigated in vivo. To address this, we developed a plasmid, pGFLIP, that encodes a sensitive Flp recombinase-
based fluorescent reporter system able to document gene activation both in vitro and in vivo. Using pGFLIP, we demonstrated
that cyaA, considered to be a “late” Bvg phase gene, is activated substantially earlier in B. bronchiseptica than B. pertussis fol-
lowing a switch from Bvg to Bvg phase conditions. We show that the altered activation of cyaA is not due to differences in the
cyaA promoter or in the bvgAS alleles of B. bronchiseptica compared to B. pertussis, but appears to be species specific. Finally, we
used pGFLIP to show that flaA remains repressed during infection, confirming that B. bronchiseptica does not modulate to the
Bvg phase in vivo.
Bordetella species are Gram-negative bacterial respiratorypathogens. The genus includes Bordetella pertussis, an obligate
human pathogen and the causative agent of whooping cough, and
the closely related Bordetella bronchiseptica, which can infect a
wide range of mammals, including several species that are com-
monly studied in the laboratory (1–3). These bacteria rely on the
global two-component regulatory system BvgAS for virulence (1–
3). The BvgAS phosphorelay regulates gene expression patterns
according to environmental cues and controls at least three dis-
tinct phenotypic phases: Bvg minus (Bvg), Bvg plus (Bvg), and
Bvg intermediate (Bvgi) (4, 5). All evidence thus far suggests that
the Bvg phase is necessary and sufficient for infection and that
modulation to the Bvg or Bvgi phase does not occur in vivo (6–8).
Although it has been hypothesized that the Bvgi phase and/or the
Bvg phase is required for transmission or survival outside a host
(7, 9, 10), a recent study provided evidence that neither of these
phenotypic phases is required for B. bronchiseptica transmission in
swine (8).
Genes that define these three phenotypic phases have been di-
vided into four classes based on their expression profile. Class 1
(late Bvg phase) genes include cyaA (encoding the bifunctional
hemolysin/adenylate cyclase toxin ACT) and ptxA (encoding the
catalytic subunit of the AB5-type pertussis toxin) (4). Class 2 (early
Bvg phase) genes include those encoding filamentous hemagglu-
tinin (fhaB), fimbriae (fim2 and fim3), and bvgAS itself (4). bipA is
the only class 3 (Bvgi phase) gene that has been characterized.
Class 4 (Bvg phase) genes include those encoding proteins in-
volved in motility (frlAB) and chemotaxis in B. bronchiseptica (4).
Expression of genes that define the various Bvg-dependent
phenotypic phases is determined mechanistically by the location
and affinity of BvgA binding sites near the transcription start site
(4). Class 1 genes contain multiple low-affinity BvgA binding sites
5= distal to the start of transcription (4, 11), while class 2 genes
contain high-affinity BvgA binding sites proximal to the tran-
scription start site (12–14). The promoter region of the class 3
gene bipA contains high-affinity BvgA binding sites 5= proximal to
the transcription start site and low-affinity sites 3= to the transcrip-
tion start site (10, 15). Although it has been hypothesized that
BvgAS directly represses transcription of frlAB in B. bronchiseptica
(16), BvgA binding to the frlAB promoter has not been demon-
strated and BvgAS-mediated repression of at least some genes in B.
pertussis is indirect (17).
In vitro transcription and DNA binding studies indicate that
the phosphorylated form of BvgA (BvgAP) is required to acti-
vate transcription of Bvg phase genes and that a higher concen-
tration of BvgAP is necessary to bind “late” Bvg phase promot-
ers than “early” Bvg phase promoters (11, 18). Although the
natural signals that activate the BvgAS system are unknown, it is
possible to modulate Bordetella spp. to the Bvg phase in the lab-
oratory by adding a chemical modulator (MgSO4 or nicotinic
acid) to the growth medium or by growing bacteria at 25°C (15,
19–21). When bacteria are grown under Bvg phase conditions,
class 4 genes are expressed while class 1 to 3 genes are not ex-
pressed. Following a switch from Bvg phase to Bvg phase con-
ditions, transcription of class 4 genes ceases and transcription of
class 2 genes, along with the sole class 3 gene bipA, is immediately
activated. After several hours, class 1 genes are expressed and class
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3 (bipA) genes are repressed. These data are consistent with the
model in which the concentration of BvgAP within the cell is
nearly zero in the Bvg phase, low in the Bvgi phase, and high in
the Bvg phase (4, 5, 11, 15, 18, 22, 23).
In contrast with the extensive in vitro characterization of the
steady-state expression patterns of BvgAS-regulated genes in both
B. pertussis and B. bronchiseptica, as well as kinetic analyses of gene
expression upon switching from modulating to nonmodulating
conditions and vice versa (5, 10, 11, 15, 22–24), only one study has
investigated BvgAS-dependent gene regulation in vivo (24). Veal-
Carr et al. utilized recombination-based in vivo expression tech-
nology (RIVET) to analyze the kinetics of BvgAS-activated gene
expression in B. pertussis both in vitro and following intranasal
infection of mice (24, 25). They showed that the in vivo activation
of Bvg phase genes, including ptxA, cyaA, fhaB, and prn, tempo-
rally recapitulated the activation pattern of these genes upon
switching B. pertussis from Bvg to Bvg phase conditions in vitro;
i.e., fhaB was activated early postinoculation (p.i.) (1 h), fol-
lowed by prn (4 h), then later by cyaA (12 h) (24). Signifi-
cantly, the fact that the patterns of gene activation were nearly
identical in bacteria switched from Bvg to Bvg phase conditions
in vitro and after inoculation of mice indicates that the mouse lung
is a Bvg phase environment (24).
We constructed a plasmid, pGFLIP, that encodes a Flp recom-
binase-based fluorescent reporter system to assess the activation
kinetics of genes in vivo (26). The region of pGFLIP delivered to
the chromosome contains gfp and nptII genes, encoding green
fluorescent protein (GFP) and neomycin phosphotransferase
(conferring kanamycin resistance [Kmr]), respectively, flanked by
Flp recombinase target (FRT) sites. The plasmid also contains a
promoterless flp recombinase gene with a multiple cloning site
(MCS) immediately 5= to the start codon. Upon expression of flp
under the control of a promoter of interest, the gfp and nptII genes
are permanently excised from the bacterial chromosome.
To test our system, we cloned the promoter regions of several
BvgAS-controlled genes, including the Bvg-activated genes cyaA,
fhaB, and ptxA and the Bvg-repressed gene flaA (encoding flagel-
lin), into pGFLIP and evaluated transcription activation in vitro
and in vivo in B. bronchiseptica. Among other results, we found
unexpectedly that the cyaA gene is expressed differently in B. per-
tussis and B. bronchiseptica.
MATERIALS AND METHODS
Strains, reagents, and growth conditions. Escherichia coli was grown in
lysogeny broth (LB; 10 g/liter tryptone, 5 g/liter yeast extract, 10 g/liter
NaCl) or on LB plates with 1.5% agar at 37°C. Bordetella was grown in
Stainer-Scholte (SS) broth (27) or on Bordet-Gengou (BG) plates with
1.5% agar (BD Biosciences, San Jose, CA) supplemented with 7.5% (B.
bronchiseptica) or 15.0% (B. pertussis) defibrinated sheep’s blood (Colo-
rado Serum Company, Denver, CO) at 37°C (28). As required, culture
media were supplemented with kanamycin (Km; 50 or 100 g/ml), am-
picillin (100 g/ml), streptomycin (Sm; 25 g/ml), MgSO4 (20 mM or 50
mM), heptakis (1 mg/ml; Sigma), and diaminopimelic acid (DAP; 400
g/ml) for the asd aphA mobilizer strain RHO3 (29). Unless otherwise
noted, all restriction enzymes and T4 DNA ligase were purchased from
New England BioLabs.
Construction of pGFLIP and derivatives containing Bordetella pro-
moters. The Tn7 transposition plasmid pUC18T-mini-Tn7T-Km-FRT
(30) was digested with BamHI, resulting in fragments of 3,636 and 1,299
bp in length containing the plasmid backbone and the nptII (Kmr) gene,
respectively. Separately, a 797-bp fragment containing gfp driven by the
constitutive Burkholderia pseudomallei rpsL promoter PS12 was amplified
by PCR from mini-Tn7-kan-gfp (31) using Pfu Ultra II (Agilent) and
primers GFP_UP and GFP_DN. This fragment was blunt-end ligated into
the cloning vector pJET1.2/blunt (Fermentas) and was transformed into
E. coli DH5 according to the manufacturer’s instructions. Using restric-
tion sites introduced by PCR, the PS12-gfp fragment was digested from
pJET using BamHI and was ligated together with the BamHI-digested
pUC18T-mini-Tn7T-Km-FRT backbone and nptII fragment. As the flp
gene would be sensitive to transcription readthrough from either the PS12
or the nptII promoter, primers specific to gfp (gfpseqR) and nptII (kan-
seqR) were used to confirm that both genes would be transcribed opposite
the promoter of interest and would therefore not drive flp expression.
Once the orientation of gfp and nptII was verified, the plasmid was di-
gested with KpnI and StuI; a fragment containing promoterless flp ampli-
fied by PCR from pFLPe4 (30) using primers FLP_UP and FLP_DN was
likewise digested with KpnI and StuI and was ligated into the digested
vector. The resulting plasmid, pGFLIP, thus contained an MCS 5= to flp,
the flp recombinase gene, and constitutively expressed nptII and gfp genes
flanked by FRT sites. pGFLIP was fully sequenced using a primer-walking
approach with the primers listed in Table 1.
Promoters for five Bordetella genes (cyaA, cyaABp, fhaB, ptxA, and
flaA) were cloned into the MCS of pGFLIP as follows. For cyaA and cya-
ABp, 605- and 604-bp fragments containing the cyaA promoter were am-
plified by PCR from B. bronchiseptica RB50 and B. pertussis BPSM, respec-
tively, using primers cyaA_F and cyaA_R. These fragments were digested
with SacI and KpnI and ligated into pGFLIP. For fhaB, a 426-bp fragment
containing the fhaB promoter was amplified by PCR from RB50 using
primers fhaprF2 and fhaprR2, digested with SacI and KpnI, and ligated
into pGFLIP. For ptxA, a 454-bp fragment containing the ptxA promoter
was amplified by PCR from BPSM using primers ptxprF and ptxprR,
digested with SacI and ApaI, and ligated into pGFLIP. For flaA, a 514-bp
fragment containing the flaA promoter was amplified by PCR from RB50
using primers flaA_F and flaA_R, digested with SacI and KpnI, and ligated
into pGFLIP. These constructs were delivered to the chromosome by
transposase-mediated insertion as described below.
Transposase-mediated delivery of pGFLIP to the B. bronchiseptica
attTn7 site. The pGFLIP plasmid was delivered to Bordetella by triparen-
tal mating using a procedure modified from reference 28. B. bronchiseptica
strains RB50 and RB52 were grown on BG agar for 48 h, and a portion of
the cells was coincubated with conjugation-competent E. coli RHO3 cells
(29) harboring pGFLIP and RHO3 cells containing the helper plasmid
pTNS3 (30), which expresses tnsABCD from a constitutive promoter, on
BG agar supplemented with DAP for 6 h at 37°C. Following incubation,
cells were restreaked onto BG-Km agar containing 20 mM MgSO4 (to
maintain strains containing pGFLIP with Bvg phase promoters in the
Bvg phase) or without MgSO4 (to maintain RB50flaAFLP in the Bvg

phase) and were incubated an additional 48 h at 37°C. Delivery of pGFLIP
to BPSM followed the same procedure except that incubations required 4
days at 37°C and plates were supplemented with 50 mM MgSO4. pGFLIP
without a promoter driving flp was used as a positive control for GFP
production and as a negative control for flp activation. The delivery of all
constructs to the attTn7 site was confirmed by PCR using primers glmSF
and gfpseqR (data not shown).
Evaluation of pGFLIP in vitro. We determined the functionality of
pGFLIP using a plate-based assay in which RB50cyaAFLP and
RB50flaAFLP were modulated between promoter-inactive and promoter-
active conditions. BG agar containing 20 mM MgSO4 was used to dere-
press PflaA and to deactivate PcyaA, while BG agar without MgSO4 was used
to activate PcyaA and to repress PflaA (7). The pGFLIP strains were grown
under promoter-inactive conditions for 48 h at 37°C and were determined
to be GFP positive (GFP) using a G:BOX Chemi imaging system with an
UltraBright-LED blue transilluminator and an SW06 short-pass filter
(495 to 600 nm; Syngene, Frederick, MD). A single GFP colony was
resuspended in PBS and was diluted and plated on BG agar under pro-
moter-active and promoter-inactive conditions. To demonstrate the loss
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of Kmr upon promoter activation, Km (100 g/ml) was added to some
plates. Plates were incubated for 48 h at 37°C, and white-light and fluo-
rescent images were obtained using the G:BOX Chemi system.
For kinetic assays, strains containing pGFLIP were grown overnight
with Km selection in SS under promoter-inactive conditions (20 mM
MgSO4 for RB50cyaAFLP, RB50cyaABpFLP, RB50fhaBFLP, and
RB50ptxAFLP; no added MgSO4 for RB50flaAFLP). Cells were washed
twice in PBS with or without 5 mM MgSO4 to prevent the premature
activation of Bvg phase and flaA promoters, respectively, and were
added to fresh SS medium under promoter-active conditions (20 mM
MgSO4 for RB50flaAFLP; no added MgSO4 for RB50cyaAFLP,
RB50cyaABpFLP, RB50fhaBFLP, and RB50ptxAFLP) at an optical density
at 600 nm (OD600) that was equivalent to 1  10
9 CFU/ml. Tubes were
incubated on a roller at 37°C for 8 h. At each time point, an aliquot of cells
was removed, diluted in phosphate-buffered saline (PBS) under promoter-
inactive conditions, and plated on BG agar under promoter-inactive con-
ditions. Plates were incubated for 48 h at 37°C, and total CFU were enu-
merated. For kinetic assays with B. pertussis, cultures were inoculated at
the CFU/ml corresponding to an OD600 of 0.1, and cells were grown
overnight in SS containing 50 mM MgSO4, 100 g/ml Km, and 1 mg/ml
heptakis. Cells were washed in PBS containing 25 mM MgSO4 to prevent
premature flp activation. All other aspects of the assay were the same as for
B. bronchiseptica, except that dilutions were plated on BG agar containing
50 mM MgSO4 and plates were incubated 4 days at 37°C. GFP fluores-
cence was quantified using the G:BOX Chemi imaging system as described
above. The percent resolution (the ratio of GFP colonies to the total
number of colonies  100%) was calculated for each strain at each time
point.
Evaluation of pGFLIP in a murine model of infection. Five- to
7-week-old BALB/c mice (Jackson Laboratories, Bar Harbor, ME) were
inoculated intranasally with 1  105 CFU of B. bronchiseptica pGFLIP
strains in 50 l of PBS. For infections with RB50cyaAFLP,
RB50cyaABpFLP, RB50fhaBFLP, and RB50ptxAFLP, bacteria were grown
overnight in SS medium containing Km (100 g/ml) and 20 mM MgSO4
to maintain cells in the Bvg phase. For infections with RB50flaAFLP,
bacteria were grown overnight in SS media containing Km (100 g/ml) to
maintain cells in the Bvg phase. Lungs were harvested from infected
mice at 1 h and 30 h postinoculation (p.i.). For RB50flaAFLP, right lungs
were homogenized in 1 ml of PBS, diluted in PBS, and plated in duplicate
on BG agar. For strains containing Bvg phase promoters in pGFLIP,
homogenization, dilution, and plating were carried out in the presence of
20 mM MgSO4. Percent resolution was calculated for each strain at each
time point. This study was done in strict accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. Our protocol was approved by the Univer-
sity of North Carolina IACUC (protocol 12-307.0). All animals were
properly anesthetized for inoculations, monitored regularly, and eutha-
nized when moribund, and efforts were made to minimize suffering.
Statistical analyses. Statistical analyses were performed using Prism 5
(GraphPad Software, Inc.). Statistical significance was determined using
the unpaired Student’s t test or analysis of variance (ANOVA). Images
TABLE 1 Primers used in this study
Primer Sequence (5=–3=)a Description
FLP_UP ATCTACGGTACCATGAGCCAGTTCGATATCC Forward and reverse primers to amplify flp from pFLPe4
FLP_DN AGGTCCAGGCCTCTATATGCGTCTATTTATG
GFP_UP ATATATGGATCCCAGCTGTTGACTCGCTTG Forward and reverse primers to amplify gfp from mini-Tn7-kan-gfp
GFP_DN ACCTGGGGATCCTTATTTGTATAGTTCATCC
Tn7seqF GAGCGCTTTTGAAGCTGATGTGCT Forward sequencing primer annealing within Tn7R
gfpseqR GATGACGGGAACTACAAGACACGT Reverse sequencing primer annealing within gfp
kanseqR ATCGCCTTCTATCGCCTTCTTGAC Reverse sequencing primer annealing within nptII
















gflpmcsF GTTGACAAAGGGAATCAGGGGATC Forward sequencing primer for inserts in the MCS
gflpmcsR GAACTGGGTGTAGCGTCGTAAGCT Reverse sequencing primer for inserts in the MCS
glmSF CAGCTGCTGTCGTACCACACGG Forward primer to confirm Tn7 insertion at glmS by PCR
cyaA_F ATTATAGAGCTCTGCGAGCAGATGCAC Forward and reverse primers to amplify PcyaA from RB50 and BPSM
cyaA_R TATAATGGTACCGTGGATCTGTCGATAAGTAG
ptxprF AGCTTCGAGCTCCAAGATAATCGTCCTGCTC Forward and reverse primers to amplify PptxA from BPSM
ptxprR ATATATGGGCCCTCCCGTCTTCCCCTCT
fhaprF2 AGGCCTGAGCTCGATAAGAAGAATATGCTT Forward and reverse primers to amplify PfhaB from RB50
fhaprR2 ATATTCGGTACCATTCCGACCAGCGAAGTG
flaA_F AATGAGCTCGCCGTGCTCAACGTCA Forward and reverse primers to amplify PflaA from RB50
flaA_R ATTATAGGTACCAGGCTCCCAAGAGAGAAA
a The underlined sequences represent restriction enzyme cut sites.
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were formatted using Adobe Photoshop CS5, and figures were generated
using Adobe Illustrator CS5 (Adobe Systems, Inc.).
RESULTS
Design and construction of pGFLIP. To study transcription ac-
tivation of genes both in vitro and in vivo, we engineered a reporter
system, pGFLIP, that provides both fluorescent and selectable
markers. We designed our system for simplicity and ease of use.
Therefore, all of the components necessary for pGFLIP function
are contained on a single plasmid. The region of pGFLIP delivered
to the chromosome includes gfp and nptII, each under the control
of a strong constitutive promoter and together flanked by FRT
sequences (Fig. 1A). The Flp recombinase gene flp is present in the
opposite orientation from gfp and nptII with an immediate 5=
MCS to facilitate the insertion of a promoter of interest. In the
absence of promoter activity, flp is not transcribed and cells re-
main GFP and Kmr. When the promoter of interest is activated,
flp is transcribed and the gene product mediates recombination
between FRT sites, permanently excising gfp and nptII.
To test the system, we cloned promoter regions from B. bron-
chiseptica and B. pertussis into the MCS to generate the strains
described in Table 2. The region of pGFLIP between the Tn7L and
Tn7R ends was delivered to the attTn7 site 3= to the glmS gene in
Bordetella spp. as described in Materials and Methods. Transcrip-
tion terminators are present near the 5= end of the transposon to
prevent transcription readthrough from glmS. Delivery of pro-
moterless pGFLIP to B. bronchiseptica RB50 and B. pertussis BPSM
resulted in strains that were stably GFP and Kmr. These strains
did not lose GFP fluorescence or Kmr when passaged multiple
times in vitro in the absence of selection (data not shown).
Functional evaluation of pGFLIP in vitro. To evaluate the
functionality of pGFLIP, we used two B. bronchiseptica promoters
for which activity can readily be induced in vitro: PcyaA and PflaA. In
B. bronchiseptica, the flaA promoter is highly transcribed in the
Bvg phase, while the cyaA promoter is transcribed strongly in the
Bvg phase (9, 10, 15, 22, 33). Therefore, RB50flaAFLP was con-
structed under Bvg phase conditions to prevent expression of
flaA, while RB50cyaAFLP was maintained under Bvg phase con-
ditions to prevent expression of cyaA. Km was added to the media
during construction of these strains to select against any bacteria
that had activated flp, thus ensuring that the population only
contained GFP and Kmr cells. To test these strains for
pGFLIP functionality, we suspended a single GFP colony of each
strain in PBS and plated on BG, BG-Km, BG-MgSO4, and BG-
Km-MgSO4 agar and observed colony formation and GFP fluo-
rescence after two (B. bronchiseptica) or four (B. pertussis) days of
incubation at 37°C.
When plated under promoter-active conditions (20 mM
MgSO4 for RB50flaAFLP; no added MgSO4 for RB50cyaAFLP) in
the absence of Km, all RB50flaAFLP and RB50cyaAFLP colonies
examined had lost fluorescence, and when tested subsequently for
growth on agar containing Km, all colonies had lost Kmr (Fig. 2A
and D). As expected, plating either strain under promoter-active
conditions and in the presence of Km resulted in a lack of growth
due to loss of nptII from the chromosome (Fig. 2E and H).
Conversely, when plated under promoter-inactive conditions
(no added MgSO4 for RB50flaAFLP; 20 mM MgSO4 for
RB50cyaAFLP) in the presence of Km, all RB50flaAFLP and
RB50cyaAFLP colonies maintained fluorescence (Fig. 2F and G).
Likewise, under promoter-inactive conditions in the absence of
Km, all RB50flaAFLP colonies maintained fluorescence (Fig. 2B),
indicating that flaA is not expressed under these conditions. Un-
expectedly, however, when RB50cyaAFLP was plated under pro-
moter-inactive conditions in the absence of Km selection, approx-
imately 14% of the colonies had lost fluorescence at the time of
imaging (Fig. 2C). These colonies did not grow when restreaked
onto BG-Km-MgSO4, indicating that cells in these colonies were
not gfp mutants but had lost fluorescence and Kmr due to Flp-
mediated recombination. These results suggest that the transcrip-
tion activity of PcyaA under Bvg
 phase conditions in vitro is close
to the threshold level of flp transcription required for Flp-medi-
ated recombination between FRT sites. These plate-based assays
for fluorescence and Kmr demonstrated that pGFLIP is indeed
functional and that both markers (gfp and nptII) can be used to
document promoter activation under active and inactive condi-
tions.
FIG 1 Design and mechanism of pGFLIP. (A) Diagram of pGFLIP. Tn7R and
Tn7L, left and right ends of the Tn7 transposon, respectively; T0 and T1, bac-
teriophage  and E. coli rrnB transcriptional terminators, respectively; FRT,
Flp recombinase target; gfp, green fluorescent protein gene; nptII, neomycin
phosphotransferase gene; MCS, multiple cloning site with restriction sites in-
dicated; flp, Flp recombinase gene; oriT, origin of conjugative transfer; ori,
ColE1 origin of replication; and bla, 	-lactamase gene. (B) Schematic illustra-
tion of Tn7-mediated delivery and Flp-mediated excision of pGFLIP in RB50.
The region of pGFLIP flanked by Tn7L and Tn7R sequences is delivered to the
attTn7 site located between glmS and BB4801. While the promoter driving
expression of the gene of interest (Pgene) remains inactive, gfp and nptII are
expressed constitutively, resulting in fluorescent and Kmr bacteria. When Pgene
is activated, flp is expressed and Flp recombinase mediates site-specific recom-
bination between FRT sites, permanently excising gfp and nptII and yielding
bacteria that are nonfluorescent and sensitive to Km.
Byrd et al.
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Kinetic analysis of Bordetella gene activation using pGFLIP.
We next assessed the ability of this system to monitor gene activa-
tion over time in bacteria grown in liquid culture. Strains contain-
ing pGFLIP plasmids with cyaA, fhaB, ptxA, and flaA promoters
were grown overnight under promoter-inactive conditions and
switched to promoter-active conditions, and the percent resolu-
tion (i.e., loss of GFP fluorescence and Kmr) was calculated over 8
h. For the first 4 h after switching from Bvg phase to Bvg phase
conditions, the percentage of RB50flaAFLP colonies that had lost
fluorescence remained below 20% (Fig. 3A), indicating that less
than 20% of the bacteria had reached or surpassed the threshold of
flp expression to result in recombination during this time. Ap-
proximately 75% of cells had lost fluorescence at 6 h, and this
proportion was maintained at 8 h (Fig. 3A). When grown under
Bvg phase conditions for 24 h, more than 85% of cells demon-
strated a loss of fluorescence and Kmr (data not shown). The fact
that resolution did not reach 100% suggests that the maximum
level of flaA expression under in vitro Bvg phase conditions (SS
medium containing 20 mM MgSO4) is just at or above the thresh-
old of flp expression needed for Flp-mediated recombination be-
tween FRT sites. The relatively long amount of time required for
the majority of RB50flaAFLP cells to cross the threshold of flp
expression is in agreement with a previous study that examined
the expression kinetics of the BvgAS-regulated operon frlAB,
which encodes the E. coli FlhDC homologs FrlAB that are at the
top of the flagellum transcription cascade in B. bronchiseptica (16).
Upon shifting from Bvg phase to Bvg phase conditions, a frlAB-
lacZ fusion strain exhibited a gradual increase in 	-galactosidase
activity over time, reaching approximately 40% of the maximum
overnight expression level by 7.5 h (15).
In contrast, when RB50fhaBFLP cells were switched from Bvg
phase to Bvg phase conditions, the fhaB promoter was appar-
ently activated as early as 1 h, at which time approximately 75% of
cells had lost fluorescence (Fig. 3A). At 2 h and later time points,
nearly 100% of RB50fhaBFLP cells had lost fluorescence, consis-
tent with the classification of fhaB as a class 2 gene requiring a
relatively low level of BvgAP for activation. As a canonical class
1 (or “late”) gene, ptxA had only been activated in approximately
8% of cells at 1 h (Fig. 3A). Approximately 20% of cells had acti-
vated ptxA by 4 h, increasing to 90% of cells by 8 h. Surprisingly,
cyaA, which is also considered to be a class 1 gene, was activated in
over 85% of cells at 1 h, and in more than 95% of cells at 2 h and
later time points (Fig. 3A). These data suggest that at early time
points after switching to promoter-active conditions, the cyaA
TABLE 2 Strains and plasmids used in this study





DH5 Molecular cloning strain 28
RHO3 Conjugation strain; Kms asd aphA 29
Bordetella
RB50 Wild-type B. bronchiseptica strain; Smr 7
RB52 RB50 containing bvgAS from BP338; Smr 22
BPSM Smr Tohama I derivative 29, 32
RB50FLP RB50 with promoterless pGFLIP integrated at attTn7 This study
RB50cyaAFLP RB50 with flp recombinase driven by PcyaA integrated at attTn7 This study
RB50cyaABpFLP RB50 with flp recombinase driven by PcyaA from Tohama I integrated at attTn7 This study
RB52cyaABbFLP RB52 with flp recombinase driven by PcyaA from RB50 integrated at attTn7 This study
RB52cyaABpFLP RB52 with flp recombinase driven by PcyaA from Tohama I integrated at attTn7 This study
RB50fhaBFLP RB50 with flp recombinase driven by PfhaB from RB50 integrated at attTn7 This study
RB50ptxAFLP RB50 with flp recombinase driven by PptxA from Tohama I integrated at attTn7 This study
RB50flaAFLP RB50 with flp recombinase driven by PflaA integrated at attTn7 This study
BPSMFLP BPSM with promoterless pGFLIP integrated at attTn7 This study
BPSMcyaAFLP BPSM with flp recombinase driven by PcyaA from RB50 integrated at attTn7 This study
BPSMfhaBFLP BPSM with flp recombinase driven by PfhaB from RB50 integrated at attTn7 This study
BPSMptxAFLP BPSM with flp recombinase driven by PptxA integrated at attTn7 This study
Plasmids
pUC18T-mini-Tn7T-Km-FRT Mobilizable transposition vector; Apr Kmr 30
pFLPe4 Site-specific excision vector, source of Flp recombinase; Apr Kmr 30
mini-Tn7-kan-gfp Mobilizable transposition vector, source of gfp driven by PS12; Kmr 31
pTNS3 Tn7 transposase expression vector containing tnsABCD; Apr 30
pGFLIP pUC18-based vector with PS12-gfp and nptII flanked by FRT sequences and flp
3= to the MCS; Apr Kmr
This study
pGFLIP-PcyaA pGFLIP with flp recombinase driven by the RB50 cyaA promoter; Ap
r Kmra This study
pGFLIP-PcyaABp pGFLIP with flp recombinase driven by the BPSM cyaA promoter; Ap
r Kmra This study
pGFLIP-PfhaB pGFLIP with flp recombinase driven by the RB50 fhaB promoter; Ap
r Kmra This study
pGFLIP-PptxA pGFLIP with flp recombinase driven by the BPSM ptxA promoter; Ap
r Kmra This study
pGFLIP-PflaA pGFLIP with flp recombinase driven by the RB50 flaA promoter; Ap
r Kmra This study
a Kmr only under promoter-inactive conditions.
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promoter is activated to a level sufficient to drive flp-mediated
recombination. This result was unexpected based on cyaA tran-
scription results in studies of B. pertussis (5, 11, 18, 23, 24).
At the initiation of each kinetic experiment, we observed a
consistent background resolution (i.e., the percent resolution at 0
h) for each Bvg phase promoter in pGFLIP. RB50cyaAFLP dis-
played the highest background resolution at 8.9%, while the back-
ground resolution for fhaB and that for ptxA were significantly
lower at 1.54% and 1.99%, respectively (P 
 0.01). The back-
ground resolution for RB50flaAFLP was the lowest of the pGFLIP
constructs at 0.23% (Fig. 3A). The fact that a portion of
RB50cyaAFLP cells had lost fluorescence at 0 h suggests that low-
level expression of cyaA might be occurring in a BvgAS-indepen-
dent manner, which could interfere with measuring BvgAS-de-
pendent PcyaA activation over time. Therefore, to test the
sensitivity of pGFLIP to background resolution, we grew
RB50cyaAFLP, RB50fhaBFLP, and RB50ptxAFLP strains over-
night as shown in Fig. 3A, washed the cells to remove Km, and
maintained the cultures under Bvg conditions in the absence of
selection for 8 h. At 0, 1, 4, and 8 h, the percent resolution was
determined for each strain. We hypothesized that if PcyaA was in-
deed active under Bvg conditions, we would observe a steady
increase in resolution over time for RB50cyaAFLP but not for
RB50fhaBFLP or RB50ptxAFLP. As expected, RB50cyaAFLP dis-
played the greatest background resolution at 11.9%, increasing to
18.1% at 8 h (Fig. 3B). Loss of fluorescence for RB50fhaBFLP and
RB50ptxAFLP remained essentially unchanged over 8 h, averaging
0.22% and 5.4%, respectively (Fig. 3B). Although cyaA had been
activated in approximately one-fifth of the population at 8 h, these
data do not account for the 85% resolution observed for
RB50cyaAFLP as early as 1 h following the switch to Bvg phase
conditions.
Neither the B. bronchiseptica bvgAS allele nor PcyaA accounts
for the unexpectedly early activation of cyaA. As cyaA expression
in RB50 was activated unexpectedly early compared to what has
been observed for B. pertussis (5, 11, 18, 23, 24), we sought to
determine whether differences in the cyaA promoter or in the
bvgAS allele between B. bronchiseptica and B. pertussis accounted
for this difference. There are five single nucleotide changes and
one nucleotide insertion in the sequence 5= to cyaA in B. bron-
FIG 2 Plate-based validation of the pGFLIP reporter system using PcyaA and PflaA. Left column, images of RB50cyaAFLP plated under Bvg
 phase (A) and Bvg
(C) phase conditions (achieved by supplementing BG agar with 20 mM MgSO4) in the presence (E) or absence (G) of 100 g/ml Km. Right column, images of
RB50flaAFLP plated under Bvg phase (B) and Bvg (D) phase conditions in the presence (F) or absence (H) of 100 g/ml Km. White light photographs are on
the left and fluorescent images are on the right in each pair of images.
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chiseptica RB50 compared to B. pertussis BPSM. We hypothesized
that replacing the cyaA promoter of RB50 with that of BPSM
would delay the activation of PcyaA relative to PfhaB, similar to what
was observed by Veal-Carr et al. (24). We cloned the cyaA pro-
moter from B. pertussis BPSM into pGFLIP and introduced this
plasmid into RB50, generating strain RB50cyaABpFLP. When eval-
uated in the kinetic assay, there was no difference in the rate of
resolution between RB50cyaAFLP and RB50cyaABpFLP, suggest-
ing that differences in the cyaA promoter do not account for the
rapid resolution observed in B. bronchiseptica (Fig. 4).
Some strains of B. pertussis, such as BP338 and BPSM, exhibit
decreased sensitivity to chemical modulation compared to B.
bronchiseptica RB50 due to amino acid differences in BvgS, which
causes these strains to remain in the Bvg phase at a lower con-
centration of modulator than RB50 (22). We hypothesized, there-
fore, that the bvgAS allele from BP338 would permit activation of
cyaA more quickly and in a greater percentage of cells than the B.
bronchiseptica RB50 bvgAS allele. To assess this, we utilized strain
RB52, which contains the entire bvgAS locus and bvgA promoter
from B. pertussis BP338 in place of bvgAS in RB50 (22). RB52
recapitulates the decreased sensitivity to modulation characteris-
tic of both BP338 and BPSM, requiring 40 mM MgSO4 to mod-
ulate to the Bvg phase, in contrast to RB50, which requires 10
mM MgSO4 to fully modulate (15, 22). We introduced pGFLIP
containing the RB50 cyaA promoter driving flp expression into
RB52, producing strain RB52cyaABbFLP. We evaluated the kinet-
ics of cyaA activation in RB52cyaABbFLP compared to
RB50cyaAFLP and did not observe any difference. Likewise, when
we evaluated an RB52 derivative containing the BPSM cyaA pro-
moter driving flp expression (RB52cyaABpFLP) in the kinetic as-
say, there was no impact on cyaA activation compared to
RB50cyaAFLP. Together, these data suggest that neither the cyaA
promoter nor the bvgAS allele significantly affects the kinetics of
cyaA activation in B. bronchiseptica as reported by the PcyaA-flp
promoter fusion in pGFLIP (Fig. 4).
Evaluation of Bordetella promoter activation in vivo. Al-
though the kinetics of Bvg phase gene activation in vivo have
been examined for B. pertussis (24), these experiments have not
been done in B. bronchiseptica or in the context of a natural bac-
terium-host interaction. To address BvgAS-regulated gene activa-
tion in B. bronchiseptica in vivo, we infected BALB/c mice intrana-
sally with 1  105 CFU of the RB50 pGFLIP strains shown in
Fig. 3A, grown under promoter-inactive conditions (100 g/ml
Km, 20 mM MgSO4). Mice were sacrificed and lungs were har-
vested at 1 h and 30 h p.i. Lungs were homogenized and dilutions
were plated on BG agar containing 20 mM MgSO4 to prevent
further recombination. Total CFU were enumerated, and the per-
centage of colonies that had lost fluorescence (percent resolution)
was calculated for each strain and time point. The percentage of
RB50fhaBFLP that had lost fluorescence at 1 h was 95.3% 
0.60%, while only 5.4%  0.69% of RB50ptxAFLP had lost fluo-
rescence at this time (Fig. 5). Similar to the in vitro kinetic assay
(Fig. 3A), the majority (85.3%  3.3%) of RB50cyaAFLP cells had
lost fluorescence at 1 h. At 30 h p.i., essentially all cells had lost
fluorescence, indicating that the environment in the mouse in-
duces the expression of Bvg phase genes to a level at or above that
required to activate flp expression (Fig. 5). The fact that the pG-
FLIP system functions in vivo much the same as in vitro when
switched from Bvg to Bvg phase conditions suggests that the
pattern of Bvg phase gene activation is similar between these two
conditions and that the unexpectedly early expression from the
cyaA promoter in vitro was not due to an artifact of that assay.
Although all evidence thus far suggests that the Bvg phase is
necessary and sufficient for Bordetella spp. to cause respiratory
infection in rats and mice (6, 7, 22, 34), it is possible that rare in
vivo environments exist that induce modulation to the Bvg
phase. Therefore, using the activation of the flaA promoter as an
FIG 4 Effect of PcyaA and bvgAS alleles on cyaA activation in B. bronchiseptica.
RB50 and RB52, an RB50 derivative carrying the bvgAS allele from B. pertussis
BP338 in place of the native bvgAS allele, each with pGFLIP containing RB50
and BPSM PcyaA, were grown as shown in Fig. 3 and were switched to promoter-
on conditions for 8 h. Loss of fluorescence was calculated for each strain as
described in Materials and Methods. Results are the means  SEM for exper-
iments performed in duplicate.
FIG 3 Kinetic analysis of Bordetella gene activation in vitro. B. bronchiseptica
strains grown under promoter-off conditions and in the presence of 100 g/ml
Km were washed and placed in fresh SS medium under promoter-on condi-
tions (A) or promoter-off conditions (B). Colonies arising from aliquots
plated over 8 h were monitored for loss of fluorescence, and the percent reso-
lution was calculated. Results are the means  standard errors of the means
(SEM) for experiments performed in duplicate or triplicate.
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indicator of the Bvg phase, we infected mice as described above
and evaluated the loss of fluorescence at 1 h and 30 h p.i. We did
not observe activation of flaA in any RB50flaAFLP cells at 1 h, 30 h,
3 days, 5 days, or 7 days (Fig. 5). These data suggest that B. bron-
chiseptica does not enter the Bvg phase in the mouse during the
time period that we examined.
Kinetic analysis of Bordetella gene activation in B. pertussis
reveals delayed activation of cyaA compared to B. bronchisep-
tica. Due to the observation that neither the cyaA promoter nor
the bvgAS allele affects the kinetics of cyaA activation in B. bron-
chiseptica, we hypothesized that additional, species-specific fac-
tors account for the differences in the activation of cyaA. To eval-
uate this possibility, we delivered the same pGFLIP plasmids as
those used in B. bronchiseptica to the chromosome of B. pertussis
BPSM and evaluated loss of fluorescence in the kinetic assay. We
reasoned that if the activation of cyaA, fhaB, and ptxA in B. per-
tussis resembled the pattern seen in B. bronchiseptica, then the
discrepancy with the study by Veal-Carr et al. (24) was likely due
to differences in recombinase expression sensitivity between pG-
FLIP and RIVET (i.e., Flp recombinase is activated at a lower
threshold of PcyaA activity than TnpR, making cyaA appear to be
activated sooner in the Flp-FRT system). Alternatively, if activa-
tion of cyaA, fhaB, and ptxA was canonical as in Veal-Carr et al.
(24), then the difference in cyaA activation would be attributed to
species-specific gene regulation.
In contrast to what we observed in B. bronchiseptica, the pro-
portion of BPSMcyaAFLP that had lost fluorescence at 1 h was less
than 10%, essentially equal to the level of background resolution
(Fig. 6). There was a steady loss of fluorescence in BPSMcyaAFLP
beginning at 2 h postswitch and continuing until 6 h, at which
time more than 90% of colonies had lost fluorescence. The pattern
of PcyaA activation in B. pertussis matched that of PptxA, which
displayed similar but somewhat earlier activation in B. pertussis com-
pared to B. bronchiseptica (Fig. 6). Interestingly, the loss of fluores-
cence in BPSMfhaBFLP occurred more slowly than in RB50fhaBFLP,
with approximately 55% of cells having lost fluorescence at 1 h. At 2 h
postswitch, the proportion of GFP BPSMfhaBFLP equaled that of
RB50fhaBFLP at 1 h, indicating that the activation of PfhaB may be
delayed in B. pertussis compared to B. bronchiseptica; however, the
background resolution for BPSMfhaBFLP (29.5%  11.3%) was
substantially higher than RB50fhaBFLP. At 1.99%, the background
resolution for BPSMptxAFLP was identical to that seen for
RB50ptxAFLP, while the background for BPSMcyaAFLP (4.8% 
2.2%) was not significantly different compared to RB50cyaAFLP
(Fig. 6).
DISCUSSION
Evaluating bacterial gene expression within the host is critical for
understanding the complex host-pathogen interactions that result
in disease, clearance, or asymptomatic colonization. One ap-
proach that has been developed to evaluate gene expression in the
host is in vivo expression technology (IVET) (35). In IVET, pro-
moter sequences are cloned 5= to a gene that either confers resis-
tance to an antibiotic or complements a specific auxotrophy (35–
37). Under conditions in which the promoter is active, these genes
are expressed and permit the survival of bacteria in hosts that have
either been dosed with the relevant antibiotic (for antibiotic resis-
tance-based selection) or naturally lack the ability to complement
the auxotrophy (for auxotrophy-based selection) (35). A draw-
back of using IVET is that promoters that are activated transiently
or at a low level may not be identified due to insufficient produc-
tion of the missing survival factor (35). In RIVET, a modification
of IVET, a promoter of interest drives the expression of a site-
specific recombinase that irreversibly excises a genetic marker,
often an antibiotic resistance gene (24, 35, 38). By selective plating,
it is possible to determine if the promoter of interest was active at
some time during infection. Unlike IVET, RIVET permits the de-
tection of transiently or weakly expressed genes because the re-
combinase-mediated loss of a marker need only occur once to
document promoter activation (35).
pGFLIP is a pUC18-based plasmid that, while conceptually
similar to RIVET, possesses several advantages over this well-char-
acterized genetic tool. The Tn7 transposon system specifically de-
livers sequences to the attTn7 site located 3= to the highly con-
served glmS gene, which provides pGFLIP with an especially broad
host range that includes many Gram-negative bacteria (39). As a
result of this specific recombination at the attTn7 site, only one
FIG 5 Analysis of Bordetella gene activation in vivo using pGFLIP.
RB50cyaAFLP, RB50fhaBFLP, RB50ptxAFLP, and RB50flaAFLP were grown
as shown in Fig. 3, and 1  105 CFU was inoculated intranasally into mice in a
total volume of 50 l. Mice were sacrificed at 0, 1, and 30 h p.i., with additional
time points at 3, 5, and 7 days for RB50flaAFLP, and lungs were homogenized
and plated on BG agar supplemented with 20 mM MgSO4 and Sm (for
RB50cyaAFLP, RB50fhaBFLP, and RB50ptxAFLP) or on BG agar supple-
mented only with Sm (for RB50flaAFLP). Loss of fluorescence was calculated
for each strain as described in Materials and Methods. Results are the means 
SEM for experiments performed in duplicate with three mice per time point.
FIG 6 Kinetic analysis of Bordetella gene activation in vitro in B. pertussis.
Strains grown under promoter-off conditions and in the presence of 100
g/ml Km were washed and placed in fresh SS medium under promoter-on
conditions. Colonies arising from aliquots plated over 8 h were monitored for
loss of fluorescence, and the percent resolution was calculated. Results are the
means  SEM for experiments performed in triplicate.
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integration event is required for all components of pGFLIP to be
delivered in single copy to the bacterial chromosome. Single-copy
delivery eliminates potential gene dosage issues inherent to mul-
ticopy plasmid systems, and integration at the attTn7 site does not
disturb the native locus of the gene to be tested. Once delivered, a
Tn7 transposon is stable in the absence of selection, unlike suicide
plasmids that have been integrated into the chromosome via sin-
gle-crossover homologous recombination, which can spontane-
ously resolve in the absence of selection. In contrast with other
published systems, pGFLIP also possesses two markers—gfp and
nptII—allowing either the loss of fluorescence or Kmr to indicate
promoter activation.
In this study, we used pGFLIP to analyze the transcription
activation of Bvg-regulated genes in both B. bronchiseptica RB50
and B. pertussis BPSM. Our results showed that, in vitro, fhaB and
ptxA promoters were activated early and late, respectively, follow-
ing a switch from Bvg to Bvg phase conditions, which is in
agreement with previous reports for both Bordetella species (15,
23, 24). However, the cyaA promoter was activated unexpectedly
early in our assay; these results appear to stand in contradiction to
the established view that cyaA is transcribed solely as a late gene.
Using B. bronchiseptica RB50 in a BALB/c mouse model, we found
that the pattern of gene activation for cyaA, fhaB, and ptxA was
nearly identical to that observed in vitro at early time points. Veal-
Carr et al. reported similar agreement between in vitro and in vivo
gene activation patterns using RIVET (24), although in that study,
maximal activation of fhaB, cyaA, and prn occurred over a much
greater time scale (approximately 24 h to full activation), likely a
result of differences in sensitivity between the TnpR-res and Flp-
FRT systems. Our use of pGFLIP to evaluate gene activation in B.
bronchiseptica is both the first kinetic analysis of PcyaA and the first
in vivo kinetic analysis of any promoter to be reported for this
organism.
Although we expected PcyaA to behave like a class 1 promoter in
B. bronchiseptica, based on gene activation and expression data
obtained by us and others for B. pertussis (5, 11, 18, 23, 24), our
data nevertheless suggest that PcyaA acts more like a class 2 pro-
moter in this organism. However, it is not necessarily the case that
cyaA reaches maximal expression at 1 to 2 h following a switch
from Bvg phase to Bvg phase; it is possible that cyaA activation
occurs in a stepwise manner, i.e., PcyaA may rapidly reach a level of
expression necessary to activate flp transcription in our system,
but may not reach maximal expression until much later. This sce-
nario would account for the apparently rapid activation of PcyaA
without requiring a bacterium to be producing and secreting a
significant amount of ACT immediately upon switching to non-
modulating conditions. Evidence exists to support cyaA activation
and ACT production, albeit at a reduced level, in the Bvgi phase, as
strains RB50i and RB53i are slightly hemolytic on BG agar (a con-
sequence of the hemolysin activity of ACT), and RB53i produces
measurable levels of cyaA transcript (9). We were able to deter-
mine that neither differences in the cyaA promoter nor differences
in the bvgAS allele between the two species accounted for the dif-
ference in cyaA activation (Fig. 4), suggesting that other (poten-
tially Bvg-independent) factors may be influencing cyaA activa-
tion in B. bronchiseptica compared to B. pertussis.
In B. pertussis BPSM, PcyaA demonstrated an activation pattern
consistent with both indirect (RIVET) and direct (RNA hybrid-
ization) assessments, reinforcing the conclusion that cyaA activa-
tion is indeed different between RB50 and BPSM (23, 24). Given
the differences in host range and the ability of B. bronchiseptica to
survive outside a host (7, 9, 10, 34), it is possible that the relatively
early activation of cyaA in B. bronchiseptica is advantageous during
the establishment of infection in a mammalian host or in trans-
mission between hosts. Previous studies have shown that RB50
cyaA deletion mutants are more susceptible to clearance from the
mouse respiratory tract, presumably as a result of neutrophil-me-
diated killing, and that ACT may interact with FHA (an “early”
Bvg gene) on the cell surface and modulate cytokine production
by the host (40, 41). All strains of B. bronchiseptica that have been
tested show the same modulation characteristics in vitro (i.e., the
same relatively low concentration of modulator is required for
inducing the Bvg phase), while B. pertussis isolates exhibit vari-
able resistance to modulation at concentrations of modulator
equal to or greater than for B. bronchiseptica (22). These observa-
tions suggest that early expression of cyaA may not be detrimental
to human-adapted B. pertussis but may be necessary for B. bron-
chiseptica to establish an infection.
For both B. bronchiseptica and B. pertussis, it has been shown
that the Bvg phase is necessary and sufficient for infection (6, 7,
9, 16, 22). Our results do not contradict these observations for B.
bronchiseptica, but they demonstrate that once inside the host,
bacteria begin to transcribe Bvg phase genes within 1 h p.i., with
essentially every cell having activated fhaB, cyaA, and ptxA by 30 h
p.i. The transition of B. bronchiseptica from Bvg phase to Bvg
phase upon inoculation also indicates that the mouse lung is a
Bvg phase environment. We likewise provided evidence that B.
bronchiseptica does not modulate to the Bvg phase in vivo, sup-
porting studies conducted using Bvg phase-locked mutants that
were unable to establish an infection and were quickly cleared
from the respiratory tract and those using Bvg phase-locked mu-
tants that displayed no colonization defect (7, 8). Moreover, ecto-
pic expression of flagellin in Bvg phase B. bronchiseptica results
in impaired persistence in the rat respiratory tract, possibly due to
an immune response to this antigen (16). Therefore, modulation
to the Bvg phase likely does not occur in vivo, as it would be
disadvantageous to bacterial survival. We cannot rule out the pos-
sibility, however, that some Bvg RB50flaAFLP bacteria did mod-
ulate to the Bvg phase and were quickly eliminated by the im-
mune response or were present in a niche other than the lung
(such as the trachea or nasopharynx) and were not represented in
the lung homogenates that we analyzed. It is also conceivable that
B. bronchiseptica is able to partially modulate, perhaps to the Bvgi
phase, which would not be documented using RB50flaAFLP. We
are currently constructing additional strains to test this possibility.
The pGFLIP plasmid has proven to be useful in understanding
the regulation of gene activation in Bordetella. However, there
remain caveats for the use of this system in other applications. As
with other IVET and RIVET systems, pGFLIP requires that strains
be manipulated under strict promoter-inactive conditions to pre-
vent unwanted Flp-mediated resolution. This requirement poses
problems for studying genes for which conditions of repression or
lack of activation are unknown, genes that are essential for growth,
and genes that may not be fully transcriptionally inactive in vitro.
Additionally, like other systems that have been developed to mon-
itor transcription, pGFLIP cannot provide information about
posttranscriptional or posttranslational regulation of target genes.
Finally, as was shown by the variable background resolution of
Bvg-regulated promoters in our study, pGFLIP appears to be sen-
sitive to low-level promoter activation even under “repressed”
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conditions for certain genes. Lee et al. were able to modulate the
sensitivity of RIVET by mutating the ribosome binding site (RBS)
of tnpR, effectively raising the threshold of promoter activity re-
quired for resolution (42). pGFLIP does not possess an RBS 5= to
flp, instead relying on the RBS of the promoter of interest, though
it would be feasible to develop a modified pGFLIP plasmid that
contains an RBS with reduced sensitivity to permit the study of
genes that are not fully inactive or are constitutively active at a low
level.
In this study, we used pGFLIP to detect the activation of
BvgAS-regulated genes in Bordetella, but there are additional uses
for this system to measure transcription activation at the popula-
tion or single cell level. Using pGFLIP, fluorescence can be used to
quickly differentiate cells that have activated the promoter of in-
terest from those that have not. Over time, stochastic and/or tran-
sient promoter activation can result in sectoring of fluorescent
colonies, permitting spatiotemporal observation of gene activa-
tion within a single colony (M. S. Byrd and E. Mason, unpublished
observation). The addition of a second, non-gfp-encoded fluores-
cent label (e.g., a constitutively expressed fluorescent protein or a
fluorescently labeled antibody) to cells already containing pGFLIP
would allow cells that had activated the promoter of interest to be
differentiated from cells that had not. Cells labeled using such an
approach could be visualized using fluorescence-activated cell
sorting or by microscopy. We are currently developing an im-
proved pGFLIP plasmid that contains a constitutively expressed
fluorescent protein gene not flanked by FRT sites that will provide
a two-color to one-color readout upon activation of flp by the
promoter of interest. The development of pGFLIP has resulted in
a sensitive genetic tool that can be used to document promoter
activation in a broad range of Gram-negative bacteria both in vitro
and in vivo. Our use of pGFLIP to document the activation of
Bvg-regulated promoters revealed unexpectedly early activation
of cyaA in B. bronchiseptica, suggesting a possible explanation for
the less restrictive host range of this organism compared to B.
pertussis, and is the first in vivo use of a recombination-based ge-
netic reporter of B. bronchiseptica gene activation.
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